https://www.selleckchem.com/pr....oducts/eidd-1931.htm
623), followed by PF-06410293, CinnoRA, BI 695501, ABP50, Exemptia, SB5, adalimumab, and FKB327 (SUCRA = 0.39; no difference was observed in ACR20 response rates between biosimilars and adalimumab. Although statistically non-significant, differences in safety ranking were observed for serious adverse events (SAEs) among the interventions, with MSB11022 presenting the highest probability of being safe (SUCRA = 0.865) and Exemptia the lowest (SUCRA = 0.30. No significant difference was detected between adalimumab biosimilars and the
Like
Comment
Share
